Clinical Trial Update: A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects [Phase 2]

View source ↗

Summary

A completed Phase 2 study evaluating the safety and clinical activity of HCV-796 in treatment-naive and non-responder patients with Hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• HCV-796

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED